

Genopole (Évry-Courcouronnes), November 10, 2020

Covid-19 detection

An ultra-rapid new test for immediate quarantine of infected persons

Enalees and Bertin Technologies have developed jointly with Pasteur Institute, an ultra-rapid Covid-19 test more reliable than saliva and antigenic tests, to be used in the field for a delivery of results in less than 30 minutes.

Jointly developed by Enalees, a biotech situated at the heart of the Genopole Biopark, and Bertin Technologies, a new ultra-rapid Covid-19 test is marketed to companies and communities. Used in the field without professional training, the test result is obtained in less than 30 minutes. It provides a solution to the congestion in diagnostic laboratories and integrates with the diagnostic systems of communities or businesses, enabling the immediate identification and isolation of an infected person.

- ▶ The nasal swab used in this test is less invasive and painful than the nasopharyngeal swab used in conventional PCR,
- ▶ Test result is obtained from a portable reader easily transported throughout different environments and even remote locations,
- ▶ The test is reimbursed by the French universal health insurance.

In order to **support the development** of this test, the Greater Paris regional government has just awarded two grants for a total amount of € 400,000 to Bertin Technologies and Enalees, respectively located in Yvelines and Essonne, as part of the PM'up Covid-19 call for proposals.

Carrying the CNR(National reference center) labelling, the test is also registered by the Ministry of Social Affairs and Health **through its Covid-19 platform (BEC SARS-CoV-2 RT-LAMP kit for human samples).**

The reliability of the RT-LAMP based BEC test was evaluated by the national reference center for respiratory infections in Lyon and deemed equivalent to RT-PCR, the gold standard in diagnostic testing, according to its published report.

In accordance with the recommendation of WHO (World Health Organization) and HAS (Haute Autorité de Santé), the BEC test includes two target genes of SARS-CoV-2 and one endogenous control for the validation of proper sampling and correct sample preparation for acceptable result interpretation.

Statement from **Laurent Thierry**, CEO and Co-founder of **Enalees**:



The grant from Greater Paris permits Bertin Technologies and Enalees to accelerate the perfection of the BEC tests towards the goal of CE-IVD labelling for the human test. Through us, the high level of confidence and interest that the regional government has in all Greater Parisian biotech companies are demonstrated.

Statement from **Bruno Vallayer**, Managing director of **Bertin Technologies**:



Registration of the BEC test on the official site of the Ministry of Health following the evaluation from CNR of Lyon enables reimbursement by the French universal healthcare for the use of BEC-SARS-CoV-2 for humans. As of today, this test is the only rapid test evaluated by CNR that was developed and made in France, and the grant serves as an important step in its commercialization.

About Bertin Technologies: Bertin Technologies, subsidiary of CNIM, relies on its long history of innovation to develop, produce, and market innovative systems and instruments around the world. The company is active globally. Its instrumentation activity is represented by the BERTIN INSTRUMENTS brand. Its innovative measurement and sampling solutions are aimed at high-demand markets:

- ▶ Life Science (air sampler, processing of biological samples, bioanalysis kits, digital microscopy),
- ▶ Nuclear and radioprotection (portable equipment of radioprotection, radioactivity surveillance of the environment, radioactivity detection gates, professional radon gas monitoring,
- ▶ Defense, Security and Safety: Protection of sites, forces, and critical infrastructures (detection of the NRBC threat, optronic surveillance modules, and sensor networks by subsidiary Exensor.

www.bertin-instruments.com

About Enalees: Enalees is a French company founded in 2015 at the heart of the Genopole biopark, in the Paris suburb Evry-Courcouronnes. Enalees develops, produces, and markets molecular diagnostic tests for infectious diseases affecting companion animals (horses, cats, and dogs) such as equine influenza, leptospirosis, and Lyme disease. These innovative tests are simple, rapid, and field-deployable, used by veterinarians directly during consultations. The first tests for equine infectious diseases were launched in 2019 and are already used by half of all equine clinics in France. Enalees has since developed tests for cats and dogs, bringing the total number of tests to 39, available in Europe and soon in North America.

www.enalees.com

About Genopole: A French biopark dedicated to genomic research and biotechnologies related to health and environment, Genopole comprises 83 biotech companies, 17 research laboratories, 25 technological platforms, and training centers of universities (University of Evry, Paris Saclay). The objective : creation and support of biotech companies and industrialization of technologies, promotion of the development of life science research, development of high-level teaching in these fields. Managed by Gilles Lasserre, Genopole, located in Evry-Courcouronnes, is mainly supported by the State, the Greater Paris Region, the Department of Essonne, the intercommunal Greater Paris Sud, the City of Evry-Courcouronnes and the AFM-Telethon.

www.genopole.fr

Contact Enalees

Laurent THIERY, PhD
CEO and Co-founder
06 32 512 519
laurent.thiery@enalees.com

Contact Bertin

Gootenberg Agency
Laurence Colin
06 49 75 47 11
laurence.colin@gen-g.com

BERTIN
Charlotte Riquier
Marketing Director
06 07 42 16 53
charlotte.riquier@bertin.fr

Contact Genopole

Anne Rohou
Journalist
01 60 87 83 10
anne.rohou@genopole.fr